28/02/2026
When patients read about new sinus injections and biologic therapies, they often assume surgery can be avoided in every case.
Biologics such as dupilumab are approved for selected patients with chronic rhinosinusitis with nasal polyps and work by targeting specific inflammatory pathways. Europe's EPOS 2020 guidelines recommend careful patient selection based on disease severity and response to standard therapy.
What does this mean in India? Most sinus patients improve with medical therapy and, when required, endoscopic sinus surgery. Biologics are reserved for severe, uncontrolled cases and require long term follow up.
Cost, access and continuity of care must be considered before choosing advanced treatment.
Understanding your diagnosis is the first step before deciding on medicines or surgery.